Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Merck
AstraZeneca
McKinsey
McKesson

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR EXALGO


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Exalgo

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01207596 ↗ Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain Completed International Clinical Research Institute Phase 4 2010-09-01 The purpose of this study is to find out if Exalgo (r) is beneficial for the patients with neuropathic pain.
NCT01455519 ↗ True Functional Restoration and Analgesia in Non-Radicular Low Back Pain Completed Mallinckrodt Phase 4 2011-10-01 You are asked to take part in this study because you have chronic, non-radicular low back pain. This study is done to investigate the pain relieving effects of the study drug Exalgo (Hydromorphone ER) for people who experience chronic non-radicular low back pain. The purpose of this research is to look at how the study drug can be used to benefit people who experience this type of pain. This is a phase IV study done to study the safety and effectiveness of the drug. At this point the drug has been approved by the Food and Drug Administration and has been studied in more than 2,000 pain patients in clinical trials, including individuals with low back pain. About 36 subjects will take part in this study.
NCT01455519 ↗ True Functional Restoration and Analgesia in Non-Radicular Low Back Pain Completed Rehabilitation Institute of Chicago Phase 4 2011-10-01 You are asked to take part in this study because you have chronic, non-radicular low back pain. This study is done to investigate the pain relieving effects of the study drug Exalgo (Hydromorphone ER) for people who experience chronic non-radicular low back pain. The purpose of this research is to look at how the study drug can be used to benefit people who experience this type of pain. This is a phase IV study done to study the safety and effectiveness of the drug. At this point the drug has been approved by the Food and Drug Administration and has been studied in more than 2,000 pain patients in clinical trials, including individuals with low back pain. About 36 subjects will take part in this study.
NCT01455519 ↗ True Functional Restoration and Analgesia in Non-Radicular Low Back Pain Completed Shirley Ryan AbilityLab Phase 4 2011-10-01 You are asked to take part in this study because you have chronic, non-radicular low back pain. This study is done to investigate the pain relieving effects of the study drug Exalgo (Hydromorphone ER) for people who experience chronic non-radicular low back pain. The purpose of this research is to look at how the study drug can be used to benefit people who experience this type of pain. This is a phase IV study done to study the safety and effectiveness of the drug. At this point the drug has been approved by the Food and Drug Administration and has been studied in more than 2,000 pain patients in clinical trials, including individuals with low back pain. About 36 subjects will take part in this study.
NCT01517295 ↗ Pharmacokinetic Study of Hydrocodone/APAP in Chronic Pain Patients Completed International Clinical Research Institute Phase 4 2012-02-01 Objective is to evaluate the pharmacokinetics profile of hydrocodone's metabolite hydromorphone in patients who are taking hydrocodone on a routine basis for more than 3 months for chronic pain and correlate hydromorphone levels to their hydrocodone usage.
NCT01517295 ↗ Pharmacokinetic Study of Hydrocodone/APAP in Chronic Pain Patients Completed Medtronic - MITG Phase 4 2012-02-01 Objective is to evaluate the pharmacokinetics profile of hydrocodone's metabolite hydromorphone in patients who are taking hydrocodone on a routine basis for more than 3 months for chronic pain and correlate hydromorphone levels to their hydrocodone usage.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Exalgo

Condition Name

Condition Name for Exalgo
Intervention Trials
Pain 2
Intraoperative Complication 1
Liver and Intrahepatic Bile Duct Disorder 1
Low Back Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Exalgo
Intervention Trials
Anemia, Sickle Cell 1
Neoplasms, Second Primary 1
Acute Pain 1
Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Exalgo

Trials by Country

Trials by Country for Exalgo
Location Trials
United States 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Exalgo
Location Trials
Texas 2
Kansas 2
California 1
Wisconsin 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Exalgo

Clinical Trial Phase

Clinical Trial Phase for Exalgo
Clinical Trial Phase Trials
Phase 4 4
Phase 3 3
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Exalgo
Clinical Trial Phase Trials
Completed 5
Recruiting 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Exalgo

Sponsor Name

Sponsor Name for Exalgo
Sponsor Trials
National Cancer Institute (NCI) 3
M.D. Anderson Cancer Center 2
International Clinical Research Institute 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Exalgo
Sponsor Trials
Other 11
NIH 5
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Colorcon
Moodys
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.